Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Zasocitinib (TAK-279) in Healthy Adults
NCT06258265Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zasocitinib in plaque psoriasis and psoriatic arthritis (PsA) (4 arms), sponsored by Takeda. Primary endpoint: Placebo-corrected Change From Baseline in QTc Interval. Started Apr 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06258265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06258265.